Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

What was studied

This mid-stage trial, called FLUORO, tested a chemo-free plan for follicular lymphoma. The patients had no earlier treatment. Their tumour burden was high. They got atezolizumab and obinutuzumab for 6 cycles. After cycle 2, very low dose radiotherapy (4Gy) went to all PET-avid sites. Obinutuzumab then ran on for 2 years. 15 patients could be assessed for response. The median age was 53 years.

What they found

Complete response was the main goal. It was reached in most patients assessed. All patients assessed had an objective response. Median follow-up was 41 months. The abstract gives 3-year progression-free and overall survival rates. Grade 3-4 side effects occurred in some patients, and 2 were immune-related. Baseline PET and gene activity profiles looked like possible markers of response to immunotherapy.

What it means for patients

The authors say the combination showed efficacy and safety. They say it may offer a chemo-free option. They say more studies are warranted on low-cost radiotherapy to boost immunotherapy.

Why it is not certain yet

Only 15 patients could be assessed. This was a mid-stage trial. It had no comparison group. The markers for response are early. The authors call the chemo-free option potential.

Source

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.